Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

 

05-09-2019

 

 

Reata Pharmaceuticals First Quarter Financial Results and Update on Development Programs

Webcast: click here
Press (05-02-2019): Reata Pharmaceuticals, Inc. Announces First Quarter and to Provide Update on Development Programs on May 9, 2019

Press (05-09-2019): Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs

Teleconference Information

Date: Thursday, May 9, 2019
Time: 8:00 a.m. ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 5177169

Read more

 MP3      PDF

02-28-2019

Reata Pharmaceuticals Management Call

Webcast: click here
Press (02-28-2019): Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results
Press (02-21-2019): Reata to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs

Teleconference Information

Date: Thursday, February 28, 2019
Time: 8:00 a.m. ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 8569879

Read more

 MP3      PDF

02-20-2019

Reata Pharmaceuticals Management Call

Webcast: click here
Press: Reata Announces Positive Phase 2 Data For Bardoxolone Methyl In Patients With Focal Segmental Glomerulosclerosis And In Patients From All Four Cohorts Of Phoenix

Webcast Information

Date: Wednesday, February 20, 2019
Time: 8:00 a.m. ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Conference ID: 6555059

Read more

 MP3      PDF

Events and Presentations

05-2019

Corporate Presentation

 PDF

04-16-2019

April 2019

S.H. Subramony, M.D., Professor of Neurology, University of Florida, Gainesville, FL, presented Baseline Characteristics in Part 2 of “MOXIe” Trial: A Study of the Efficacy and Safety of Omaveloxolone in Patients with Friedreich’s Ataxia.

 PDF

04-13-2019

April 2019

Colin Meyer, M.D., Chief Medical Officer, Reata Pharmaceuticals, presented Rationale and Design of “CARDINAL”: A Phase 2/3 Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome.

 PDF

04-02-2019

CNBC Interviews Reata CEO Warren Huff

Video Thumbnail
Reata CEO on drug that shows signs of reversing kidney damage